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Identification of an allosteric binding site
for RORgt inhibition
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RORgt is critical for the differentiation and proliferation of Th17 cells associated with several
chronic autoimmune diseases. We report the discovery of a novel allosteric binding site on
the nuclear receptor RORgt. Co-crystallization of the ligand binding domain (LBD) of RORgt
with a series of small-molecule antagonists demonstrates occupancy of a previously
unreported allosteric binding pocket. Binding at this non-canonical site induces an
unprecedented conformational reorientation of helix 12 in the RORgt LBD, which blocks
cofactor binding. The functional consequence of this allosteric ligand-mediated conformation
is inhibition of function as evidenced by both biochemical and cellular studies. RORgt function
is thus antagonized in a manner molecularly distinct from that of previously described
orthosteric RORgt ligands. This brings forward an approach to target RORgt for the treatment
of Th17-mediated autoimmune diseases. The elucidation of an unprecedented modality of
pharmacological antagonism establishes a mechanism for modulation of nuclear receptors.
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N
uclear receptors (NRs) modulate transcription of
particular sets of genes on binding of small lipophilic
ligands and thereby regulate physiological parameters of
cellular function1. NRs are also important pathological regulators
in diseases such as cancer, diabetes and autoimmune disorders.
This combination of characteristics of NRs has given rise to some
of the most notable pharmaceutical agents of the past century2.
The retinoic-acid-receptor-related orphan receptor (ROR) is a
NR subclass that demonstrates great therapeutic potential3.
In particular, RORgt, whose activity is required for the
proliferation and functionality of immune Th17 cells, is the
subject of intense investigation to modulate its activity to achieve
clinical benefit4–6. Th17 cells exert an inflammatory, pathological
role in autoimmune diseases7,8 and on stimulation produce pro-
inflammatory cytokines9. Antibodies directed against the cytokine
IL17 have been clinically successful, proving the potential of
targeting the Th17/IL17 axis10. Active RORgt is a prerequisite for
the differentiation of T cells into Th17 cells11,12. Small-molecule
inhibition of RORgt has therefore been brought forward as a
novel strategy for the treatment of autoimmune diseases13,14.
NRs are characterized by the ability to bind small ligands at a
highly conserved hydrophobic orthosteric-binding pocket located
within the protein’s ligand-binding domain (LBD)1. A typical NR
LBD exhibits a three-layered fold of B12 alpha helices and 2–3
b-strands. Ligand binding in this pocket can activate or inhibit
the receptor to various degrees15. Helix 12 (H12, also called
activation function-2, AF-2) can adopt distinct conformations in
response to ligand binding, regulating the interaction of the
LBD with cofactor proteins with resulting changes in gene
transcription at a particular locus. Typically, on the binding of an
agonist, H12 is stabilized in a conformation that facilitates the
binding of a coactivator16,17. Conversely, antagonist binding
induces a different H12 conformation unsuitable for coactivator
binding. NR drugs thus bind to this orthosteric-binding pocket
and act as molecular ‘switches’ that control NR transcriptional
activity due to the positioning of H12 (ref. 18). This canonical
ligand binding is associated with selectivity issues and mutation-
induced antagonist/agonist switches for different NRs and
therefore molecules that occupy allosteric-binding sites on NRs
are highly sought after19–21. Such allosteric modulation might be
expected to induce conformational effects that are not dependent
on competition with endogenous ligands and could provide
enhanced potency/efficacy or greater specificity over canonical
ligands.
We previously identified a novel series of RORgt inhibitors22.
Here we characterize the mode of action of these inhibitors to
guide an optimization program and surprisingly find a novel
binding mode, thereby identifying the first allosteric-binding
pocket for a highly potent, cellular active small NR ligand.
Structural, biochemical and cellular data reveal that the
unprecedented allosteric-binding modality confers both high
potency and selectivity to RORgt for these novel antagonists.
Results
Helix 12 repositions to generate a novel binding pocket.
Literature suggests that the RORs feature ligand-independent
transcription, with their LBDs partially in a conformation
promoting coactivator binding23. Biological data and the co-
crystal structures of RORgt LBD bound to hydroxycholesterols24,
and synthetic inverse agonistic ligands such as T0901317 (Fig. 1a)
have shown that the RORgt LBD is still structurally responsive to
ligands. For RORgt, reports suggest that multiple small molecules
affect antagonism via binding to the canonical orthosteric site13.
A high-throughput screen for molecules that disrupt the
interaction of the RORgt-LBD with steroid receptor
coactivator-1 (SRC-1) cofactor peptide, followed by a hit
optimization program, led to the identification of indazoles as a
novel class of RORgt inhibitors, typified by MRL-871 (Fig. 1a)22.
To elucidate the molecular basis of RORgt modulation by
MRL-871, we performed co-crystallization studies with an
equimolar complex of RORgt-LBD and MRL-871. Co-crystals
grew in two different space groups (Table 1). Crystals in space
group R32:H had unit cell dimensions of a¼ b¼ 173.8,
c¼ 67.2 Å, diffracted to 2.3 Å resolution and contain one
molecule per asymmetric unit. Crystals in space group P6122
had unit cell dimensions of a¼ b¼ 108.5, c¼ 104.7 Å, diffracted
to 2.2 Å resolution and also contain one molecule per asymmetric
unit. The experimental electron density maps from both
conditions showed clear density for all features of the protein,
including MRL-871. The overall structures from both sets were
identical in all the features and the ligand conformation. The
RORgt LBD crystallized with the typical NR arrangement of
helices 1–11, but with the H12 positioned in a conformation
unprecedented for all NR LBD complexes reported to date
(Fig. 1c, green). On top of that, the crystal structure revealed the
binding site of MRL-871 to be different from the canonical
orthosteric NR ligand-binding site. MRL-871 binds instead to a
previously unidentified allosteric pocket in the RORgt LBD,
located distal to the classical binding site (Fig. 1c, orange). Crystal
structure analysis shows that this allosteric pocket, absent in the
classical NR-folding motif, is formed by helices 4, 5, 11 and the
reoriented flexible H12 (Fig. 1b). The ortho-substituted
trifluoromethyl and chloro moieties are spatially clearly
positioned and impart a specific rotation to the phenyl group of
MRL-871 and address hydrophobic sites in the allosteric pocket
(Fig. 1b,d). Hydrogen-bonding interactions exist between the
molecule’s carboxylic acid group and the side chain of RORgt
residue Q329 as well as the main-chain amide hydrogen atoms of
residues A497 and F498. Apart from these distinct polar
interactions, the newly generated allosteric pocket is
predominantly hydrophobic, because of the amino-acid side
chains of residues on helices 4, 5, 11 and, notably, H12 and the
activation function loop between helices 11 and 12 (AF-2
domain). The arrangement of the RORgt LBD in the presence
of MRL-871 generates a druggable molecular-binding site
critically regulated by favourable interactions of MRL-871 with
the AF-2 domain. These interactions reposition the highly flexible
H12 in a conformation unique among reported NR ligand
structures, of either the agonist or antagonist type, and distinct
from the previously reported RORgt agonist-bound state1,6,13,14.
The unique conformation induced by the binding of MRL-871
prevents interaction with cofactor peptides, which typically bind
RORgt through a conserved LXXLL motif, at the AF-2.
Functional RORct inhibition via allosteric inverse agonism.
To determine the functional effect of the binding of these novel
modulators and the resulting RORgt conformational changes,
two variants of MRL-871 (MRL-058 and MRL-003) were also
prepared and tested alongside an agonist and canonical inverse
agonist in an AlphaScreen cofactor peptide recruitment assay.
Indazoles MRL-871 and its derivatives MRL-058 and MRL-003
all inhibited coactivator binding in a dose-dependent manner
(Fig. 2a) with half-maximum inhibitory concentration (IC50)
values of 7±1 nM (MRL-871), 98±23 nM (MRL-058) and
280±117 nM (MRL-003), showing the antagonistic profile of the
series. Cholesterol, binding as agonist to the LBD, functioned
as a weak activator, further enhancing the interaction of the
RORgt–LBD with a cofactor peptide25. The inverse agonist
T0901319 demonstrated an IC50 value of 24±13 nM in this assay,
which is in good agreement with previously reported values, but
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less potent than MRL-871 (refs 26,27). The data thus show that
the allosteric-binding mode of the novel modulators as observed
in the crystal structures translates into potent inhibition of
coactivator peptide binding to RORgt–LBD. Furthermore, these
data also indicate that both ortho-substituents on the benzamide
moiety are required to enhance RORgt-binding affinity, which
suggest that the observed binding mode in the crystal structure is
most optimal.
To corroborate our structural findings and gain more insight in
the mode of action for these compounds, competitive binding
assays for both MRL-871 (Fig. 2c) and T0901317 (Fig. 2d) were
performed against fixed concentrations of cholesterol. On the
basis of the structural data, we hypothesized that MRL-871
should not compete with cholesterol for the orthosteric ligand-
binding pocket, because they bind into different pockets. As such,
the IC50 value of MRL-871 for inhibition of the RORgt
coactivator interaction should be independent of cholesterol
concentration. Increasing concentrations of cholesterol increase
the RORgt coactivator interaction, in line with the agonistic
properties of cholesterol, as evidenced by an increased fluores-
cence ratiometric level with cofactor peptide (Fig. 2c,d).
MRL-871, however, effectively antagonizes the RORgt coactivator
peptide recruitment interaction, independent of cholesterol
concentration. The competitive cofactor-binding assay for
MRL-871 showed no significant change in IC50 value when
performed in the presence of different concentrations of
cholesterol (Fig. 2c). In contrast, the inverse agonist T0901317
competes for the same binding site as cholesterol, resulting in a
competitive displacement and a cholesterol concentration-
dependent increase of the IC50 value for T0901317 (Fig. 2d);
that is, RORgt binding and inhibition by T0901317 becomes less
potent in the presence of agonistic ligands. Together, these data
demonstrate that the allosteric inhibition of coactivator binding
to RORgt by MRL-871 is both potent and independent of
orthosteric site occupancy.
RORgt mediates IL17a gene expression in EL4 cells4. The EL4
murine lymphoblast cell line constitutively expresses RORgt,
which drives production of IL17a (ref. 28). To confirm that
allosteric RORgt modulation has also functional relevance at the
cellular level, EL4 cells were treated with 10 mM of modulators
MRL-871, MRL-058 and MRL-003 for 24 h and IL17a messenger
RNA (mRNA) levels were measured by quantitative reverse
transcriptase PCR (RT–PCR) (Fig. 2b). Treatment of EL4 cells
with the more potent MRL-871 and MRL-058 significantly
reduced the IL17a mRNA levels, while the weaker MRL-003 did

















































































































Figure 1 | Co-crystal structure of RORct with MRL-871. (a) Chemical structures of a representative orthosteric ligand T0901317 (ref. 27), binding to
the canonical site of NRs, and indazoles MRL-871, MRL-058 and MRL-003. (b) Zoomed-in view of MRL-871 in the novel allosteric-binding pocket of
RORgt formed by helices 4, 5, 11 and 12. MRL-871 shown as orange sticks in the electron density. The RORgt residues involved in hydrophobic interactions
and hydrogen bonding are shown as white and green sticks, respectively. (c) Superposition of RORgt (blue) in complex with orthosteric ligand T0901317
shown in red (PDB ID 4NB6)26 and RORgt (green) in complex with MRL-871, shown in orange. MRL-871 (orange) sits in a new allosteric pocket in
direct contact with H12 inducing its repositioning. Orthosteric ligand T0901317 destabilizes H12, which is therefore not visible in the blue structure.
(d) A two-dimensional plot showing the interactions between MRL-871 and the surrounding amino acids.
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biochemical activity observed for this compound. This result thus
demonstrates that functional modulation of the allosteric pocket
by small molecules results in cellular responses (that is, reduced
gene transcription).
Structural basis for ligand potency. The cofactor recruitment
assay described above provides an indirect assessment of
modulator potency since the site of cofactor interaction does not
directly overlap with the binding site of the indazoles. Therefore,
an orthogonal assay that directly and selectively probes the
novel allosteric RORgt-binding site is desirable for screening,
characterization and optimization purposes. We used the
co-crystal structure of RORgt and MRL-871 (Fig. 1c) to rationally
design a synthetic ligand analogue containing a time-resolved
fluorescence resonance energy transfer (TR-FRET) acceptor.
AlexaFluor 647 was connected to the six position of MRL-871 via
a short molecular spacer (Supplementary Fig. 1); this site of the
molecule protrudes into an open channel in the crystal structure.
This probe molecule proved to have a robust TR-FRET signal at
low concentrations in the presence of His-tagged RORgt–LBD
and an anti-His Europium chelate antibody. Titration studies
in a TR-FRET assay revealed a Kd of 100±24 nM with the
RORgt–LBD (Supplementary Fig. 1). When the parent MRL-871
was tested for the ability to compete with the allosteric probe, the
resulting IC50 value was similar to that observed in cofactor
recruitment assays (Table 2).
We explored the synthetic optimization of MRL-871 to establish
structure–activity relationships around the indazole series. These
compounds were tested in biochemical assays, including the
competition assay using the fluorescent-labelled allosteric probe,
cellular chimeric receptor reporter assays in HEK-293 cells and
Th17 differentiation/IL17a production assays in primary human
peripheral blood mononuclear cells (PBMCs), as well as structural
studies (Fig. 3). Table 2 describes several informative examples.
MRL-299 features two additional fluoro groups, one at the
indazole ring and one at the phenyl substituent. MRL-367 contains
additional polar functionality—the phenyl substituent contains a
hydroxyl substituent ortho to the carboxylic acid, and the C-4 of
the indazole is replaced by nitrogen. In the case of MRL-673, the
benzoic acid functionality is saturated, and the carbon atom
adjacent to the carboxylate is alkylated, resulting in a tetrasub-
stituted carbon centre. This modification induces a displacement of
the carboxyl group and highlights the importance of the polar
interactions in the binding site.
The additional fluorine groups (MRL-299) and the polar
functionalities (MRL-367) were both important for RORgt-
binding potency and functional inhibition (Table 2). In particular,
MRL-367 exhibited enhanced potency in the cofactor displace-
ment and direct binding assay, as well as increased inhibitory
activity in a luciferase reporter assay and in functional inhibition
of IL-17 production. To insure that the functional activity of the
indazole series is attributable to inhibition of RORgt, MRL-299
was tested against a commercially available panel of cell-based
NR reporter assays (Supplementary Table 1). Across this panel of
NR assays, MRL-299 was 4100-fold selective for RORgt. The
only significant off-target activity was against PPARg (PPARg
activity was also recently reported for a structurally similar series
of molecules29), which was de-risked (Supplementary Note 1).
Structural elucidation of these compounds reveals that all
antagonists occupy the same allosteric-binding pocket as
MRL-871 (Fig. 3). Detailed comparison of, for example,
MRL-871 and MRL-367 (Fig. 3b) reveals that both polar
molecular additions to the scaffold are fully tolerated and lead
only to very minor changes in the surrounding amino-acid
orientations. MRL-673, in contrast, exhibits 10-fold weaker
Table 1 | Data collection and refinement statistics (molecular replacement).
PDB ID 4YPQ 5C4O 5C4U 5C4S 5C4T
Ligand name MRL-871 MRL-871 MRL-367 MRL-299 MRL-673
Data collection
Space group R32:H P 61 2 2 P 61 2 2 P 61 2 2 P 61 2 2
Cell dimensions
a, b, c (Å) 173.8, 173.8, 67.2 108.5, 108.5, 104.7 108.1, 108.1, 106.5 108.4, 108.4, 106.3 107.3, 107.3, 100.4
a, b, g () 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (Å) 35.47–2.32 (2.40–2.32)* 69.91–2.24 (2.32–2.24) 93.6–2.08 (2.154–2.08) 93.92–2.23 (2.31–2.23) 92.9–1.77 (1.836–1.77)
Rsym 0.121 (0.886) 0.047 (1.45) 0.0420 (1.236) 0.056 (1.402) 0.0565 (1.239)
I/sI 12.1 (2.7) 35.91 (2.57) 38.87 (2.62) 30.03 (2.51) 29.46 (2.61)
Completeness (%) 100.0 (100.0) 99.94 (99.89) 99.78 (99.36) 99.99 (100.0) 99.99 (100.00)
Redundancy 11.7 (11.6) 16.0 (15.8) 19.3 (19.9) 18.8 (19.2) 19.1 (19.7)
Refinement
Resolution (Å) 35.47–2.32 69.91–2.24 93.6–2.08 93.9–2.23 92.9–1.77
No. reflections 16882 17932 22579 18547 33582
Rwork/Rfree 0.174/0.227 0.227/0.266 0.228/0.273 0.218/0.261 0.192/0.223
No. atoms
Protein 1987 1996 1994 1987 1985
Ligand/ion 32 60 51 45 118
Water 130 14 23 18 101
B-factors
Protein 45.70 67.90 59.80 67.9 39.6
Ligand/ion 41.50 102.5 57.70 64.1 50.50
Water 47.30 64.20 57.80 63.9 45.30
R.m.s. deviations
Bond lengths (Å) 0.008 0.014 0.014 0.014 0.015
Bond angles () 1.04 1.78 1.81 1.75 1.64
R.m.s., root mean squared.
*Values in parentheses are for highest-resolution shell.
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potency in both the biochemical and cellular assays relative to
MRL-367. Structural comparison of, for example, MRL-367 and
MRL-673 (Fig. 3c) reveals that, while these compounds bind the
same allosteric site, the position of the carboxylate ring of
MRL-673 distorts the binding pocket. The modification induces a
displacement of the carboxyl group and highlights the importance
of the polar interactions in the binding site. Although the
carboxylate of MRL-673 makes the same number of polar
contacts with RORgt as MRL-367, the methylation induces the
reorientation of the side chains of Phe498 and Tyr502. This shift
in the side chains and the accompanying shifts in the backbone of
the C-terminal residues of Ala497 and Phe498, explains the lower
receptor affinity and functional inhibitory potency.
Discussion
NR drug development has been based primarily on the ability of
NRs to bind ligands at the highly conserved hydrophobic
orthosteric pocket of the LBD, which is also the binding site of
endogenous ligands1,18. Compared with unbound NRs, the
binding of an agonist induces a conformational change that
stabilizes the positioning of H12 and AF-2 domain, resulting in
coactivator recruitment. The binding of antagonist or inverse
agonist ligands typically destabilizes H12 and the AF-2 domain
(possibly unfolding it) resulting in a lack of coactivator or
enhanced corepressor recruitment, ultimately resulting in
transcriptional inhibition at specific loci. Numerous successful
drugs targeting NRs have been developed, all working via this
mechanism, but increasing resistance against certain cancer
therapy oriented NR antagonists, as well as the challenge of
targeting orphan receptors has increased the need for alternative
site modulators of NRs19–21. Similar to, for example, the efforts
to target allosteric sites in protein kinases30, allosteric NR
modulators may differentiate favourably versus orthosteric
ligands. Potential advantages of allosteric NR inhibitors are
enhanced selectivity, no competition with increasing endogenous
ligands during pathological conditions, and no sensitivity to
agonist/antagonist switching due to mutations.
The recently reported crystal structure of RORgt with a potent
tertiary amine orthosteric agonist revealed the coactivator-
binding site on the LBD, in a classical NR H12 switch agonist
mode and bound to a cofactor peptide motif (Fig. 4a)31. The new
crystal structures of RORgt reported here with MRL-871 and its
analogues (Fig. 3) reveal that these indazole modulators bind to a
receptor position normally occupied by H12 in the non-liganded
or agonist ligand-bound conformation. The final orientation of
H12 in the presence of the novel indazole modulators is such that
the classical binding surface for the cofactor LXXLL motif is not
only modified, but actively blocked (Fig. 4e). This overall
orientation effectively antagonizes cofactor binding to RORgt.
The consequence of this allosteric modulator-mediated refolding
of RORgt is functional inhibition as evidenced by biochemical
and cellular studies. The unique mode of allosteric binding
reported thus provides a structural rationale for targeting NRs
with small molecules in an orthogonal manner that does not
require competition with canonical ligands.
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Figure 2 | Allosteric inhibition. (a) TR-FRET assay showing the effect of the agonist cholesterol, the inverse agonist T0901317 and indazoles
MRL-871, MRL-058 and MRL-003 on cofactor recruitment to the RORgt LBD in a dose-dependent manner. MRL-871, MRL-058, MRL-003 and T0901317
function as inhibitors, while cholesterol promotes cofactor binding to RORgt. Error bars are defined as s.d. (n¼ 3). (b) IL17a mRNA expression in EL4 cells
treated with MRL-871, MRL-058, MRL-003 (10 mM, 24 h) or DMSO. The level of IL17a mRNA expression was normalized to that of GAPDH expression. All
data are expressed as the mean±s.e.m. (n¼6). Statistical analysis was performed using an one-way analysis of variance comparing against the DMSO
control following Dunnett post hoc test. Error bars denote s.e.m. **Po0.01. (c) Inhibition of cofactor binding by the allosteric modulator MRL-871 is
independent of cholesterol concentration (IC50 4.7±1.4 nM; 2.5±0.9 nM; 1.8±1.5 nM; 2.3±1.8 nM at 0, 1, 10 and 25 mM cholesterol, respectively).
Error bars are defined as s.d. (n¼ 3). (d) Inhibition of cofactor binding by ligand T0901317 depends on cholesterol concentration (IC50 11±3.4 nM;
18±4.9 nM; 195±59 nM; 548±152 nM at 0, 1, 10 and 25mM cholesterol, respectively). Error bars are defined as s.d. (n¼ 3).
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The X-ray structures demonstrate that these indazoles all
occupy the novel allosteric binding pocket. Reported crystal
structures with orthosteric inverse agonists, binding to the
canonical site of RORgt, lack clear structural data for the
position of the H12 and the resulting cofactor-binding site
(for example, Fig. 1c with T0901317 and Fig. 4b). Synthetic
RORgt inverse agonists T0901317 (ref. 27) and tertiary
sulfonamides26 bind at the canonical orthosteric NR ligand-
binding pocket. Their binding distorts the structure of the
LBD, leading to helices 110 and 12 being unstructured in the
crystallized protein (Fig. 4b). A superposition of the RORgt
structures with an inverse agonist in the orthosteric site and an
indazole modulator in the allosteric site reveals the additional
benefit of the novel site (Fig. 1c; Supplementary Fig. 4).
Whereas both compounds induce the partial unfolding of
helix 110 (ref. 32), MRL-871 subsequently also stabilizes the
folding of H12 via direct interactions. The unfolded helix 110
spans the distance to the displaced H12 N terminus (Fig. 4d).






























(n=8) (n=5) (n=322) (n=7)
(n=8) (n=4) (n=12) (n=12)
(n=8) (n=4) (n=7) (n=6)

































FRET, fluorescence resonance energy transfer; IC50, half-maximal inhibitory concentration; SRC1, steroid receptor coactivator 1.
*For a representative dose–response curve see Supplementary Fig. 2.
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This results in RORgt taking on a stably folded antagonistic
state and directly blocking cofactor peptide binding (Fig. 4e).
These antagonists thus induce a conformational change in
the RORgt LBD, which blocks cofactor binding through the
stabilization of the H12 subdomain in an unprecedented folded
state (Fig. 5).
In summary, we demonstrate the structural and functional
elucidation of an unprecedented NR allosteric inhibitory
mechanism, based on highly potent small-molecule modulators
for RORgt. This is the first allosteric binding pocket with
highly potent small drug-like molecules, functionally active in
Th17 differentiation/IL17a production inhibition. This allosteric
inhibitory mechanism offers great advantages for NR drug
development, including selectivity, independence of endogenous
ligands and less responsive to point mutations within the
orthosteric ligand binding site. RORgt regulates a variety of
physiological processes and has emerged as a highly promising
drug target for autoimmune diseases. The discovery of this novel
allosteric NR pocket and concomitant selective molecules that
target this site offers a new strategic opportunity to develop





Figure 3 | Co-crystal structure of RORct with MRL-871, MRL-299, MRL-367 and MRL-673. (a) Overlay of RORgt (green) co-crystallized with MRL-871,
MRL-299, MRL-367 and MRL-673. For an overall structural comparison of RORgt in complex with MRL-299 and MRL-367 see Supplementary Fig. 3.
(b) Magnified view of the overlay of MRL-871 (orange) and MRL-367 (cyan) in the novel allosteric binding pocket of RORgt (overall root mean squared
deviation (r.m.s.d) 0.219). (c) Magnified view of overlay of MRL-367 (cyan) and MRL-673 (yellow) in the novel allosteric binding pocket of RORgt (overall
r.m.s.d 0.38). MRL-673 is a racemic mixture and the two isomers are depicted. Arrows highlight repositioning of the side chains of residues Tyr502 and














Figure 4 | Molecular mechanism of allosteric RORct modulation. (a) Agonistic conformation of RORgt31 (PDB entry 4NIE) showing the position of the
agonistic ligand (red) in the classical orthosteric ligand binding site. Helices 110 and 12 (yellow) of the LBD are folded in a stable agonistic conformation,
supporting binding of the LXXLL cofactor peptide (blue). (b) Antagonistic conformation of RORgt14 (PDB entry 4QM0) induced by a classical inverse
agonist (purple) in the classical orthosteric ligand-binding site. Helices 11 and 12 of the LBD are unstructured (arrow). (c) Superposition of a and b. When
H12 is disordered, the LXXLL cofactor peptides lack a complementary surface for binding to RORgt (d) Antagonistic conformation of RORgt, induced by
allosteric modulator MRL-871 (orange). MRL-871 makes direct contact with H12 (brown) at the allosteric site in the RORgt LBD and stabilizes the folding of
H12. (e) Superposition of a and d. The binding of the allosteric modulator MRL-871 results in unfolding of helix 110 and shifts the position of H12 to directly
block cofactor peptide binding. For a structural comparison with agonist hydroxycholesterol liganded RORgt see Supplementary Fig. 5.
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Methods
Synthesis of indazole series. For the synthesis of the 3-iodo-1H-indazol-1-yl
(phenyl)methanone, thionyl chloride was added dropwise to the appropriate
benzoic acid in an oven dried flask. The reaction mixture was stirred at 75 C
overnight. After removal of the thionyl chloride under reduced pressure, the
benzoyl chloride was dissolved in dry CH2Cl2. To this solution, 3-iodo-1H-indazole
and DMAP were added. Finally, triethylamine was added dropwise and the mixture
was stirred at room temperature for 24 h. The reaction mixture was then diluted
with H2O and CH2Cl2. The layers were separated and the aqueous layer was
washed with CH2Cl2. The combined organic layers were washed with brine, dried
over Na2SO4, filtered and evaporated. The crude material was purified via column
chromatography.
For the cross-coupling reaction the appropriate 3-iodo-1H-indazole,
(4-(methoxycarbonyl)-phenyl)boronic acid, Pd(PPh3)4 and CH3CO2K were
dissolved in dioxane/H2O (5:1 v/v) in a Schlenk tube and the reaction was stirred at
90 C. After 3 h, the mixture was allowed to cool to room temperature and diluted
with CH2Cl2 and H2O. The organic layer was washed with brine, dried over
Na2SO4, filtered and concentrated. The obtained crude material was purified via
column chromatography.
To obtain the free acid, LiOH  H2O was added to a solution of the methyl ester
in THF/H2O. The reaction was stirred at room temperature. After 24 h, the
reaction was diluted with H2O, neutralized with acetic acid (BpH 4) and extracted
with CH2Cl2. The combined organic layers were washed with brine, dried over
Na2SO4, filtered and evaporated. The final products (for example, MRL-871) were
purified via preparative liquid chromatography-mass spectrometry (LCMS). For
complete synthesis and characterization data see Supplementary Methods.
HTRF assay. The human RORgt LBD used for the HTRF assay was expressed as a
His6-tag fusion protein from the pET15b expression vector in Escherichia coli
BL21(DE3) cells. Cells transformed with this vector were grown in 2 YT
medium supplemented with ampicillin until an OD600¼ 0.7 was reached. Protein
expression was then induced with 0.1 mM isopropyl-b-d-thiogalactoside (IPTG).
After incubation for 16 h at 16 C, cell cultures were collected by centrifugation.
The cells were lysed via sonication and the protein was purified via Ni2þ -affinity
column chromatography.
The homogeneous TR-FRET assays were performed in triplicate with 20 nM
His6-RORgt and 100 nM biotin labelled cofactor peptide. Terbium-labelled anti-
His antibody (cat. no: 610HATAA, 0.71 nM) and D2-labelled streptavidin (cat. no:
610SADLA, 41.7 nM) were used at recommended concentrations by the supplier
Cisbio Bioassays. Assay buffer contained 100 mM HEPES (pH 7.5), 100 mM NaCl,
5 mM dithiothreitol (DTT) and 0.1% bovine serum albumin. The plates (white
384-well plates Greiner Bio-One) were incubated for 2 h at 4 C before the FRET
ratio was measured in a Tecan Infinite F500 plate reader. The data were analysed
using Origin software. Dose–response curves were fitted following:
y ¼ A1 þ
A2 A1
1þ 10 log x0ð Þ xð Þp ;
where A1 is the botom asymptote, A2 is the top asymptote and p is the Hill slope.
RORct-LBD SRC-1 cofactor FRET assay. RORgt LBDs of from human (Genbank
accession number NP_005051 aa259–518) and mouse (Genbank accession number
NP_035411 aa236–516) were amplified by PCR and cloned into pET47b to include
the sequence MAHHHHHHHHENLYFQGTPE N terminal to the first residue of
the RORgt-coding sequence. Proteins were expressed in BL21(DE3) E. coli grown
in LB media. Expression was induced with 0.1 mM IPTG and allowed to continue
for 16 h at 16 C. Cells were lysed in 50 mM Tris, 300 mM NaCl, 10 mM imidazole,
5% glycerol, 10 mM beta-mercaptoethanol, 1% Triton X-100 and 0.2 mM PMSF,
pH 8.5 using a microfluidizer. After removal of cellular debris by centrfugation,
lysates were loaded onto Ni-NDA resin and washed with 50 mM Tris, 300 mM
NaCl, 20 mM imidazole, 5% glycerol and 10 mM beta-mercaptoethanol at pH 8.5.
The column was washed with the same buffer containing 60 mM imidazole, and
protein was eluted with the above buffer containing 250 mM imidazole. The
proteins were dialysed into 50 mM Tris, 100 mM NaCl, 5% glycerol and 1 mM
DTT, pH 8.5 for storage at  80 C. The potency of small-molecule RORgt ligands
was then assessed by monitoring their effect on the association of a LXXLL-motif-
containing SRC-1 peptide. Compound (10 mM dimethylsulphoxide (DMSO)
stock) was serially diluted in threefold steps using an Agilent Bravo liquid handler.
Diluted compound or DMSO (25 nl) was transferred into a black Greiner 384-well
plate (Cat#781076) using a LabCyte Echo acoustic dispenser. To each well of the
plate was added 15ml of 3.75 nM RORgt-LBD in receptor buffer (50 mM Tris-HCl
pH 7.0, 50 mM potassium chloride, 1 mM EDTA, 0.1% delipidated bovine serum
albumin, 1 mM DTT, 1.25 nM Anti-His W1024 Europium chelate antibody
(PerkinElmer) and 3% (v/v) of lysate from B24,000 Sf9 cells). Compounds were
allowed to incubate with receptor for 15 min and then 5 ml of peptide in detection
buffer or detection buffer alone were added. Detection buffer (5 ) consists
of 50 mM Tris-HCL pH 7.0, 50 mM potassium chloride, 1 mM EDTA, 0.1%
delipidated bovine serum albumin, 1 mM DTT and 20 nM streptavidin-APC
(PerkinElmer). When peptide (Biotin-SPSSHSSLTERHKILHRLLQEGSP) was
included, its concentration in the 5 stock was 250 nM. The plate was then
incubated overnight at 4 C. The following morning the plate was warmed to room
temperature and read using an Envision plate reader (PerkinElmer). TR-FRET
signal was defined as the ratio of the fluorescence emission at 615 to 665 nm
following excitation at 337 nm. The per cent activity of each dilution was deter-
mined as the ratio of background corrected signal to the background corrected
signal of wells receiving only DMSO. IC50 values were determined by fitting per
cent activity data to a four-parameter logistic dose–response equation in GraphPad
Prism (GraphPad Software).
RORct-LBD AlexaFluor-647-labelled MRL-871 competitive binding assay. As
an alternate assessment of inhibitor potency MRL-871 was covalently labelled with
Alexa Fluor-647. To determine the intrinsic affinity of the probe, the compound
(5 mM DMSO stock) was serially diluted in threefold steps using an Agilent Bravo
liquid handler. Diluted probe or DMSO (25 nl) were transferred into a black Greiner
384-well plate (Cat#781076) using a LabCyte Echo acoustic dispenser. To each well
of the plate was added 15ml of RORg-LBD at 1.6, 3.33 and 6.65 nM in receptor buffer
or receptor buffer alone. The plate was then incubated for 15 min at room tem-
perature. Subsequently, 5ml of receptor buffer with 1.2 nM Anti-His W1024 Euro-
pium chelate antibody (PerkinElmer) was added and the TR-FRET signal measured
as in the SRC-1 cofactor recruitment assay described above. TR-FRET intensity in the
presence of RORgt was corrected for background and the KD determined using the
One-site specific binding equation in Graph Pad Prism. To assess the potency of
unlabelled compounds, a similar assay format was utilized except that 100 nM probe
was preincubated with the RORgt-LBD for 15 min before addition to serially diluted
compounds. IC50 values were determined by fitting per cent activity data to a four-
parameter logistic dose–response equation in GraphPad Prism.
RORct crystallization and structure determination in complex with MRL-871.
A pCDFDuet-1 expression vector encoding the RORgt LBD (residues 265–507)
with an N-terminal StrepII-SUMO-tag was transformed by heat shock into
Nico21(DE3) E. coli cells (NEB). Single colonies were used to inoculate three
pre-cultures of 30 ml LB containing 100 mg ml 1 streptomycin. After overnight
incubation at 37 C, each pre-culture was transferred to 1.5 l of ZYP5052 medium33
without lactose (making ZYP505), but with 100mg ml 1 streptomycin and 0.1 %
antifoam SE-15 (Sigma-Aldrich). These cultures were incubated further until they
reached an OD600nm¼ 4. At that point, the temperature was decreased to 18 C,
protein expression was induced by adding IPTG to a final concentration of 200 mM
and the cultures were grown for 24 h more. The cells were collected by
centrifugation and were dissolved in lysis buffer (20 mM Tris pH 7.5, 300 mM
NaCl, 5 mM MgCl2, 2 mM 2-mercapto-ethanol and 10 mg ml 1 DNase I (Sigma-
Aldrich)) at 10 g per 100 ml. After cell lysis using an Emulsiflex-C3 homogeniser
(Avestin), the cell lysate was cleared by centrifugation (at 4 C) and the supernatant
was loaded on a column consisting of 10 ml Strep-Tactin Superflow High Capacity
resin (IBA). The fusion protein was eluted from the resin with three column
volumes elution buffer (20 mM Tris, 300 mM NaCl, 2 mM 2-mercapto-ethanol and
2.5 mM desthiobiotin at pH 7.5) and the StrepII-SUMO-tag was removed by
adding dtUD1 SUMO protease34. Next, the protein mixture was concentrated
using an Amicon ultra-centrifugation device with a 3-kDa cutoff (Millipore) and
loaded on a Superdex 75 pg 16/60 size-exclusion column (GE Life Sciences).




















Figure 5 | Schematic model of the novel molecular mechanism of
allosteric RORct inhibition regarding H12 folding and positioning. In the
apo form, H12 is dynamic and thus limits LXXLL cofactor binding. An
inverse agonist destabilizes H12 and lowers LXXLL binding. Agonist binding
stabilizes H12 in a optimal conformation for LXXLL binding. Binding at the
novel allosteric site, reorients the H12 of RORgt and actively blocks LXXLL
binding.
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the size-exclusion chromatography (SEC) fractions were combined and loaded for
a second time over the regenerated Strep-Tactin column. Finally, pure RORgt was
collected in the flow-through and concentrated in presence of MRL-871 to
8 mg ml 1.
Before crystallization, RORgt was mixed with an additional 1 equivalent of
ligand. The crystals were grown at room temperature using the sitting drop vapour
diffusion method. Optimal crystals were grown in a week by mixing 1 ml protein
solution with the same volume of a crystallization condition containing 0.2 M
MgCl2, 0.1 M Tris, pH 8.5 and 7% w/v polyethylene glycol 6 K. The well reservoir
was filled with 1 ml of the crystallization condition. Crystals were cryoprotected in
the mother liquor supplemented with 20 % glycerol and flash cooled in liquid
nitrogen. Diffraction data were collected at 100 K at the PX II beamline at the SLS
synchrotron (Villigen, Switzerland). iMOSFLM35 and AIMLESS36 of the CCP4
suite37 were used for integration and scaling, respectively. The structure was phased
by molecular replacement using PDB ID 4NIE31 as search model in Phaser38.
Ligand restraints were generated using Grade (Global Phasing, version 1.2.8) and
CCDC Mogul39. Coot40 and phenix.refine41,42 were used in alternating cycles of
model building and refinement. The quality of the final model was evaluated using
MolProbity43. Figures were created using PyMOL (The PyMOL Molecular
Graphics System, Version 1.7. Schrödinger, LLC) and LigPlotþ (ref. 44).
Structure coordinates were deposited in the Protein Data Bank (PDB code 4YPQ).
For a stereo image of a portion of the electron density map of the co-crystal
structure of RORgt with MRL-871 see Supplementary Fig. 6.
RORct crystallization and structure determination in complex with MRL-871,
MRL-299, MRL-367 and MRL-673. A pETDuet-1 expression vector encoding the
RORgt LBD (residues 267–507) with an N-terminal His Tag was transformed
by heat shock into E. coli BL21-Gold(DE3)pLysS (Catalog #230134, Agilent
Technologies, USA). LB Amp containing starter cultures were inoculated with
single colonies of the day before freshly transformed cells. Starter cultures were
shaken overnight. The next day 1.0 l LB Amp expression cultures were inoculated
to an OD600nm¼ 0.05 AU and incubated in 2.5 l Ultra Yield Flasks (HTS Labs,
USA) at 30 C. At an OD600nm of about 0.8 AU cultures were cooled down quickly
to 15 C. After 20 min on reaching 15 C, RORgt expression was induced by the
addition of 0.25 mM IPTG. Cells were collected 16 h after induction, resuspended
and sonicated in pre-cooled buffer A (50 mM Na2KPO4, 500 mM NaCl, 10% (v/v)
glycerol, 3 mM TCEP, 0.1% Tween20 and 2 mM CHAPS, pH 8.0) with a ratio of
cells:buffer of 1:5 (w/v). Before cell disruption, two tablets of ‘Protease Inhibitor
Cocktail, EDTA-free’ (Roche), 20 mg of lysozyme and 1800 U of benzonase were
added per 100 ml of lysis buffer and incubated on ice for 30 min under gentle
stirring. The cell paste was fluidized with two passes through a fluidizer at
12,000 p.s.i. The cell lysate was clarified by centrifugation at 48,000g for 40 min, the
supernatant was collected and the pH of the lysate was adjusted to 7.5. The sample
was loaded on to a pre-chilled HisTrap FF column (buffer A). To prepare the
magnetic beads, Ni SepFast MAG beads were washed four times with 10 bead
volumes of water and equilibrated in 20 bead volumes of buffer (50 mM phosphate,
500 mM NaCl, 2 mM CHAPS, 10 % glycerol, 3 mM TCEP, 0.1 % Tween20 and 1
tablet of complete protease inhibitor per 50 ml, pH 8.0). The supernatant obtained
was removed, the beads were washed with 20 bead volumes of buffer (50 mM
phosphate, 200 mM NaCl, 20 mM imidazole, 10% glycerol, 2 mM CHAPS, 3 mM
TCEP, 0.1 % Tween20 and 1 tablet of complete protease inhibotor per 50 ml, pH
8.0). RORgt protein was eluted from the column with (15–100%) gradient of buffer
(50 mM phosphate pH 8, 200 mM NaCl, 2 mM CHAPS, 10% glycerol, 300 mM
imidazole, 3 mM TCEP and 0.1% Tween20). The His-tag was cleaved by adding
tobacco etch virus (TEV) protease and by incubating overnight at 4 C. Efficiency
of the cleavage reaction was examined by SDS–polyacrylamide gel electrophoresis
analysis. The samples were re-run over a new HisTtrap column and the flow-
through, containing RORgt samples, were collected and concentrated to
2 mg ml 1 and flash frozen for storage.
Protein–ligand complex was prepared by mixing 1:10 molar ratio
(protein:ligand) and incubated for 2 h on ice. The sample was hard spun at 20,000g
for 20 min and was loaded onto pre-equilibrated (SEC buffer 20 mM Tris, pH 8.5,
100 mM NaCl and 2 mM DTT) S-200 SEC column. The RORgt–ligand complex
was concentrated to 10–15 mg ml 1 before crystallization. Crystals of RORgt in
complex with ligands were grown using hanging drop vapour diffusion set-ups.
A mesure of 0.2 ml of protein solution (13 mg ml 1 in 20 mM Tris, 100 mM NaCl
and 5 mM DTT, pH 8.5) was mixed with 0.2 ml of reservoir solution (1.2–1.8 M
ammonium sulfate and 0.1 M Tris/HCl, pH 8.0–9.0) and equilibrated over 0.5 ml of
reservoir solution at 20 C. Well-diffracting crystals appeared within 2 days. The
mounted crystal was flash frozen with 20% glycerol as cryo protectant in the
mother liquor. Data were collected from frozen crystals at 100 K in the facilities of
the Industrial Macromolecular Crystallography Association, at the Advanced
Photon Source located at Argonne National Laboratories in Argonne, IL. Data were
reduced and scaled using HKL2000 (HKL Research, Charlottesville, VA). The
structure was determined by molecular replacement using molrep (CCP4) and the
RORgt hydroxycholesterol structure (PDB ID: 3L0J)24 as the search model. The
structure was refined using Buster (Global Phasing); model building was performed
with coot (CCP4) and further refined with Buster. Figures were made with PyMol
(Schrödinger). Structure coordinates were deposited in the Protein Data Bank
(PDB codes 5C4O, 5C4U, 5C4S and5C4T).
Chimeric RORct-GAL4 reporter assay. The coding sequence of RORgt aa97–518
was cloned in frame with the DNA-binding domain of the yeast GAL4 protein
within the CMV-promoter-driven pCDNA3.1 vector. This vector, along with the
GAL4 UAS-luciferase reporter vector pGL4.31 (Promega), was used to transfect
HEK293T cells. Briefly, 1 107 cells in 10 ml of DMEM high-glucose media with
10% fetal bovine serum (FBS) were transfected with a mixture consisting of 10 mg
of each plasmid and 60ml of TransIT-293 (Mirus Bio) in 1.5 ml of Optimem
(Invitrogen). Following transfection, cells were transferred to one T75 flask and
incubated overnight at 37 C and 5% CO2. Compound dilutions are prepared as
above and 50 nl was transferred to a 384-well Greiner white tissue-culture-treated
plate (catalog #781080) using an Echo acoustic dispenser (LabCyte). Cells were
collected and resuspended at 0.8 106 cells per ml in DMEM high-glucose media
with 10% FBS. To each well of the plate was added 25 ml of cell suspension and the
cells incubated overnight at 37 C and 5% CO2. After 20–22 h, the plates were
brought to room temperature and 25 ml of Steady-Glo luciferase reagent (Promega)
was added to each well. The luminescent signal was measured on an Envision plate
reader.
Quantitative IL17a RT–PCR. EL4 cells (Sigma-Aldrich) were grown in DMEM
(Gibco). At 24 h after the cells were seeded onto a 12-well plate, the cells were
treated with ligands 1–3 (from 10 mM stock in DMSO) or DMSO. After 24 h, the
cells were collected and RNA was isolated using a RNeasy Plus Micro Kit (Qiagen)
and reverse transcribed using the iScrip cDNA biosynthesis kit (Bio-Rad).
Quantitative RT–PCR was performed to analyse mRNA levels of mouse IL17a
levels using SYBR green technology (Bio-Rad) on a CFX Real-Time System
(Bio-Rad). Primer sequences used for IL17a:45 Fw: 50-ctccagaaggccctcagactac-30,
Rev: 50-ctgtgtcaatgcggagggaaagct-30 and Gapdh: Fw: 50-ggtggacctcatggcctaca-30 ,
Rev: 50-ctctcttgctcagtgtccttgct-30 . The level of IL17a mRNA expression was
normalized to that of Gapdh expression. All data are expressed as the mean±s.e.m.
(n¼ 6). Statistical analysis was performed using an one-way analysis of variance
comparing against the DMSO control following Dunnett post hoc test.
PBMC Th17 polarization and IL-17 production assay. Test compounds were
prepared as 10 mM stocks in DMSO and serially diluted 1:3 to provide an eight-
concentration titration. The compounds (200 nl of each dilution) were acoustically
dispensed into a 96-well Costar 3912 assay plate. Frozen human PBMCs from an
anonymous healthy donor were obtained commercially and were diluted to a
density of 5 105 cells per ml with growth media (RPMI 1640/ 10% FBS/pen/
strep). Stimulatory cytokines were added to final concentrations of 25 ng ml 1
IL-1B, 10 ng ml 1 IL-23, 0.5 ng ml 1 IL-2 and 10 ng ml 1 IL-6 (all cytokines
from R&D Systems). In addition, T-Activator CD3/28 Dynabeads (Invitrogen)
were added to a concentration of 100,000 beads per ml. The stimulated cells were
immediately dispensed into the assay plate containing serially diluted compound at
a volume of 200 ml cells per well. Cell plates were then incubated at 37 C and 5%
CO2 for 4 days. Culture media (100 ml) was collected from each well and IL-17
expression was measured by enzyme-linked immunosorbent assay (R&D Systems)
according to the manufacturer’s instructions. Cell viability was assessed by the
addition of 100ml of CellTiter-Glo (Promega) to each well of the cell assay plate
followed by luminescence detection on an Envision plate reader (PerkinElmer).
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